Durvalumab as consolidation therapy
Durvalumab as consolidation therapy (at a dose of 10 mg per kilogram of body weight intravenously) every 2 weeks for up to 12 months, administered 1 to 42 days after the patients had received chemoradiotherapy
placebo
placebo every 2 weeks for up to 12 months
treatment received after chemoradiotherapy every 2 weeks as consolidation therapy for up to 12 months.
laNSCLC - M - all population
no specific information about EGFR or ALK status at inclusion
double-blind
NA
The overall 5% Type I error was equally split between the co-primary endpoints and the 2.5%v alpha can be recycled between PFS and OS, then hierarchical testing procedure with OS 24mo and ORR
Durvalumab therapy resulted in significantly longer OS and PFS than placebo